[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346099-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346099-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","novel-genomic-score-predicts-survival-with-immune-checkpoint-inhibition-in-neuroendocrine-neoplasms","Novel genomic score predicts survival with immune checkpoint inhibition in neuroendocrine neoplasms","","Immune checkpoint inhibition (ICI) shows activity in Grade 3 neuroendocrine neoplasms (NENs), yet long-term overall survival (OS) biomarkers remain limited. A retrospective cohort of 54 NEN patients treated with nivolumab and/or ipilimumab was used to build a composite overall genomic score (GS-O). In the ICI cohort, GS-O ≥ 2 identified patients with markedly improved OS (median not reached vs 3.9 months). GS-O was not predictive in the chemotherapy-only cohort, but remained independently prognostic in a pan-cancer validation cohort.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/novel-genomic-score-predicts-survival-with-immune-checkpoint-inhibition-in-neuroendocrine-neoplasms/346099/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/novel-genomic-score-predicts-survival-with-immune-checkpoint-inhibition-in-neuroendocrine-neoplasms/346099.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in Grade 3 neuroendocrine neoplasms?","Question",{"text":63,"@type":64},"It addresses the lack of validated biomarkers that can predict long-term overall survival after immune checkpoint inhibition in Grade 3 neuroendocrine neoplasms.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is the overall genomic score (GS-O) constructed?",{"text":68,"@type":64},"GS-O combines positive response genes (GS-P) and negative response genes (GS-N) into a single composite overall genomic score.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the study find about patients with GS-O ≥ 2?",{"text":72,"@type":64},"In the ICI cohort, GS-O ≥ 2 is associated with substantially better overall survival, with median OS not reached compared with 3.9 months for low scores.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346099,1790190771,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","The Oncologist, 2026, 31, oyag324  \n[https://doi.org/10.1093/oncolo/oyag324](https://doi.org/10.1093/oncolo/oyag324)  \n[Published: August 22](Published: August 22), 2026  \nOriginal Article  \nNovel genomic score predicts survival with immune checkpoint inhibition in neuroendocrine neoplasms  \nTanvi Brar, MD1, Charles Olowookere, BS2, Dat Le, PharmD3, Menglin Xu, PhD4, Bhavana Konda, MD, MPH5, , Vineeth Sukrithan, MD*,5,   \n1 Department of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States 2 Post Baccalaureate Program, Ohio State University, Columbus, OH 43210, United States  \n3 Department of Pharmacy, Robert H. Lurie Comprehensive Cancer Center of Northwestern, Chicago, IL 60611, United States 4 Boston Medical Center, Boston, MA 02118, United States  \n5 Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and Arthur G. James Cancer Center, Columbus, OH 43210, United States  \n*Corresponding author: Vineeth Sukrithan, Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and Arthur G. James Cancer Center, Suite 1335 Lincoln Tower, 1800 Cannon Drive, Columbus, OH 43210, USA ([Vineeth.sukrithan@osumc.edu](Vineeth.sukrithan@osumc.edu)) .  \nAbstract  \nBackground: Immune checkpoint inhibition (ICI) has activity in Grade 3 (G3) neuroendocrine neoplasms (NENs), but predictive biomarkers of long-term overall survival (OS) are currently lacking.  \nMethods: We derived a genomic scoring system using a retrospective cohort of 54 NEN patients treated with nivolumaband/or ipilimumab, alongside a chemotherapy-only control (n = 15) and pan-cancer validation cohort (n = 1661). An overall genomic score (GS-O) combining positive (GS-P) and negative response genes (GS-N) was calculated.  \nResults: In the ICI cohort, patients with GS-O ≥ 2 had significantly better outcomes: median OS was not reached, compared to 3.9 months for low scores (HR = 0.007, P \u003C .001). After multivariate adjustment, GS-P was independently associated with improved OS while GS-N showed a trend towards worsened OS. Importantly, GS-O ≥ 2 did not predict survival in the chemotherapy-alone cohort but was validated as independently predictive in the pan-cancer validation dataset (HR = 0.92, P \u003C .001).  \nConclusion: This study establishes a novel genomic score to predict OS in NENs treated with ICI with important pan-cancer implications.  \nKey words: neuroendocrine neoplasms; immunotherapy; ipilimumab; nivolumab; immune checkpoint inhibitor; biomarker; genomic score  \nImplications for practice  \nThis study has important implications for the field of immune checkpoint inhibition. We demonstrate that genomic alterations associated with positive and negative effects on the tumor-immune response have independent and opposing effects. By integrating these effects into a single composite score, we describe a predictive tool for survival benefit in patients receiving immune checkpoint inhibitors that outperforms currently utilized biomarkers in a pan-cancer fashion.  \nIntroduction  \nThe combination of anti–PD-1 and anti-CTLA-4 has an objective response rate (ORR) of between 18% (DUNE trial) and 44%(DART S1609 trial) in Grade 3 Neuroendocrine Neoplasms (NEN) .1,2 Even though the median survival ranges from 6 to 11 months, there is a subset of around 30% of patients who  \nderive a long-term survival benefit beyond the one-year mark.3 While many genomic correlates of clinical benefit and resistance to ICI have been described, there are no validated scores that can be used to predict survival.4  \nWe describe the derivation of a novel genomic scoring system that is strongly associated with survival in NENs treated with Nivolumab and Ipilimumab at a large tertiary academic medical  \nReceived: March 9, 2026. Accepted: August 10, 2026 © The Author(s) 2026. Published by Oxford University Press.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-N","cbCaifrUFeuN8KgO","https://ap.wps.com/l/cbCaifrUFeuN8KgO","pdf",1147078,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Implications for practice\n# Introduction\n# Table 1. Genomic scoring system domains and assigned scores","[{\"question\":\"What problem does the study address in Grade 3 neuroendocrine neoplasms?\",\"answer\":\"It addresses the lack of validated biomarkers that can predict long-term overall survival after immune checkpoint inhibition in Grade 3 neuroendocrine neoplasms.\"},{\"question\":\"How is the overall genomic score (GS-O) constructed?\",\"answer\":\"GS-O combines positive response genes (GS-P) and negative response genes (GS-N) into a single composite overall genomic score.\"},{\"question\":\"What does the study find about patients with GS-O ≥ 2?\",\"answer\":\"In the ICI cohort, GS-O ≥ 2 is associated with substantially better overall survival, with median OS not reached compared with 3.9 months for low scores.\"}]","Novel genomic score predicts survival with immune checkpoint inhibition in neuroendocrine neoplasms | PDF",1790060080,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c7160f6ebf4a357c25a5a09901048308.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d416047f315e9d7206d69b91e2c92f2e.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d84f7afc96a1e933871e48253c87dca.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a219aac93db9f67bb6713ed87724521.webp",980,1287]